Skip to content

Performance of CERVICHECKTM Kit, an HPV self-sampling kit for screening of cervical cancer or pre-cancerous lesions

Investigation of the performance of CERVICHECKTM Kit, an HPV self-sampling kit in comparison with clinician collected cervical sample for screening of cervical cancer or pre-cancerous lesions.

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2022/03/041084
Enrollment
150
Registered
2022-03-14
Start date
Unknown
Completion date
Unknown
Last updated
2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C539- Malignant neoplasm of cervix uteri, unspecified

Interventions

Intervention1: CERVICHECKââ??¢ Self-Sampling KIT: 1. Disposable Sample collection device with a cytobrush 2. Lubricant Gel 3. Sample Collection Media with Customer Identification Form 4. Resealable

Sponsors

Pragmatech Healthcare Solutions Pvt Ltd
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Women with a positive cervical cancer screening test report (Pap, VIA or an HPV test done outside of the study) in the past one year but without any history of treatment for a cervical abnormality 2.All the women referred to colposcopy clinic in the age group from 25 to 60 years (25 and 60 years included) 3. Women ever exposed to sex/ married women. 4. Able to understand and sign voluntarily the consent to participate or willing to provide a thumb impression.

Exclusion criteria

Exclusion criteria: 1.Women who have been treated for cervical abnormalities and now have a normal screening test report 2.Women in the menstruating phase 3.Women who are pregnant 4.Women who have used vaginal medicines in the past 1 week 5.Previous history of hysterectomy 6.Previous history of cervical cancer 7.Negative LBC/HPV less than 3 years ago

Design outcomes

Primary

MeasureTime frame
Comparison of self-sampled and clinician collected cervical cell sample for estimating Percent Positive agreement (PPA) in HPV assayed samplesTimepoint: At Baseline

Secondary

MeasureTime frame
Acceptability and feasibility of self-sampling kit based on the participants� views from a questionnaire. �The concordance for both HPV 16/18 and other high-risk HPV types separately in the self-sample and the clinician collected samples. �Estimating concordance between LBC results for self- and clinician-sampled specimens using kappa statistic. Timepoint: At Baseline

Countries

India

Contacts

Public ContactMr Anirban Palit

Pragmatech Healthcare Solutions Pvt.Ltd

anirban.palit@pragmatech.co.in8806567744

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026